Dyslipidemia is having an abnormal amount of lipids or fats in the blood.
Lipid profile is obtained from an individual with diabetes mellitus, coronary heart disease, cerebrovascular disease, peripheral arterial disease or other coronary heart disease risk factors or from an individual with family history or clinical evidence of familial hypercholesterolemia.
Plasma lipids are total cholesterol, high-density lipoprotein cholesterol, trigylcerides, and low-density lipoprotein cholesterol.
Evaluation of lipid profile must be performed in parallel with the risk assessment of coronary heart disease.
Evinacumab, a fully human monoclonal antibody inhibitor of ANGPTL3, effectively lowers LDL-cholesterol (LDL-C) levels in patients with homozygous familial hypercholesterolaemia (HoFH) regardless of their LDL receptor (LDLR) function, according to results of a double-blind phase III trial presented at the American College of Cardiology and World Congress of Cardiology virtual meeting (ACC.20/WCC).
In-hospital initiation of the PCSK9* inhibitor evolocumab, on top of high-intensity statin therapy, in the very high-risk, acute phase of ACS** significantly reduced LDL-C levels — so much so that >95 percent of the patients achieved the recommended target levels — compared with high-intensity statin alone, the EVOPACS*** study has shown.
The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.
Recently published cardiovascular outcome trials (CVOTs) in patients with diabetes (DM) have led to updates in the management of cardiovascular disease (CVD) in DM patients. These updates were reflected in the 2019 ESC guidelines on diabetes, prediabetes, and CVD, a collaboration between ESC and EASD*.
The once-daily fixed-dose combination of candesartan plus rosuvastatin reduces systolic blood pressure and low-density lipoprotein cholesterol at the same time with no major safety issues, according to the results of a phase III trial. This drug represents a convenient treatment option for patients with coexistent essential hypertension and hypercholesterolaemia.
Use of ezetimibe to manage elevated low-density lipoprotein cholesterol (LDL-C) levels in individuals aged ≥75 years proves beneficial in the primary prevention of coronary artery disease (CAD) events, reducing the risk of a composite of sudden cardiac death, myocardial infarction, coronary revascularization or stroke, according to data from the open-label EWTOPIA* 75 trial.
The three-drug combination of telmisartan, amlodipine and rosuvastatin yields significant reductions in blood pressure and low-density lipoprotein cholesterol levels in patients with hypertension and dyslipidaemia while having a good safety profile and tolerability, according to data from the J-TAROS* trial.
A dietary strategy of carbohydrate restriction proves superior to low-fat diets in terms of improving lipid markers in individuals with cardiometabolic risk, owing to its strong effects on high-density lipoprotein cholesterol and triglycerides, according to a meta-analysis.
Adherence to a beneficial lifestyle may significantly reduce the risk of chronic hypertension after hypertensive disorders of pregnancy (HDP) such as gestational hypertension and pre-eclampsia, a recent study suggests. Keeping a healthy weight appears to be critical in women with a history of HDP compared with those without such a history.
MitraClip NTR and XTR systems are effective and well tolerated for primary mitral regurgitation (MR), as shown in the prospective, multicentre, single-arm, international, post-marketing, real-world, observational EXPAND study presented at the American College of Cardiology 2020/World Congress of Cardiology (ACC.20/WCC) virtual meeting.
The Dietary Approaches to Stop Hypertension (DASH) diet is effective in reducing uric acid concentrations and risks of gout in males, a new prospective cohort study reveals. In contrast, Western diets up the risk of gout.